https://www.sirius-medical.com/news/2021/12/14/second-closing-of-a-round-financing/
Stay informed about the latest updates from Curie Capital and the ongoing activities within our portfolio companies.
PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target...
Eindhoven, the Netherlands – January 19, 2026 – Sirius Medical, the leader in surgical marker navigation, proudly announces...
Dutch life sciences VC BioGeneration Ventures led TargED’s €21.5 million Series A extension Proceeds will accelerate clinical...
- TGD001 was well tolerated with no dose-limiting toxicities across all dose cohorts, exhibiting potent thrombolytic activity -...
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as...
TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for...